StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
9
Publishing Date
2022 - 05 - 04
1
2021 - 12 - 10
1
2021 - 12 - 08
1
2021 - 11 - 12
1
2021 - 09 - 19
1
2021 - 06 - 02
1
2021 - 05 - 19
1
2021 - 03 - 18
1
2021 - 03 - 16
1
Sector
Commercial services
1
Health technology
9
Tags
America
67
Antibody
13
Application
12
Approval
21
Biosimilar
39
Breast
13
Cancer
106
Covid
17
Covid-19
12
Device
14
Diabetes
18
Diagnostics
19
Disease
76
Drug
116
Drug delivery
11
Earnings
21
Europe
17
Expansion
12
Expected
35
Eye
21
Fda
29
Financial
24
Financial results
13
Gene therapy
11
Global
229
Growing
47
Growth
263
Health
19
Immunotherapy
12
Kisqali
11
Leukemia
12
Liver
20
Market
600
N/a
1119
Novartis
136
Patent
13
People
20
Pharma
17
Pharmaceuticals
17
Pipeline
12
Positive
20
Potential
13
Reach
34
Report
195
Research
129
Respiratory
15
Results
52
Risk
11
Sales
12
Sclerosis
13
Set
17
Study
17
T-cell
12
Technology
14
Therapeutics
115
Therapy
90
Treatment
138
Trial
25
Vaccine
16
Year
12
Entities
Celcuity inc.
1
Eli lilly and company
1
Incyte corporation
1
Novartis ag
9
Symbols
A
3
AMAM
2
ANIX
4
ARAY
4
ARVN
2
ATNX
5
ATOS
4
AZN
13
AZNCF
2
BCTX
10
BIOC
4
BMY
3
BYSI
2
CELC
5
CNTX
3
DGX
2
EXAS
4
FNCTF
4
GE
2
GENE
2
GILD
22
GLAXF
3
GLSI
6
GNPX
2
GSK
3
GTHX
5
HOLX
8
ICAD
4
ICCM
2
IMMP
5
IMV
2
INCY
4
INFI
4
INMB
2
INTS
3
JAGX
4
LLY
7
MACK
2
MDT
2
MGNX
2
MRK
7
MYGN
9
NSTG
2
NTRA
3
NVS
9
NVSEF
4
NVTA
2
OCX
2
OLMA
2
ONCY
9
PBYI
5
PFE
6
PHG
3
RDUS
2
SGEN
4
SNY
6
SNYNF
4
SRNE
2
THER
2
VERU
11
Exchanges
Nasdaq
6
Nyse
9
Crawled Date
2022 - 05 - 04
1
2021 - 12 - 10
1
2021 - 12 - 08
1
2021 - 11 - 12
1
2021 - 09 - 19
1
2021 - 06 - 02
1
2021 - 05 - 19
1
2021 - 03 - 18
1
2021 - 03 - 17
1
Crawled Time
01:00
1
08:00
1
11:00
1
12:30
1
13:00
1
14:00
1
15:00
1
16:20
1
22:00
1
Source
www.biospace.com
3
www.globenewswire.com
4
www.prnewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Breast cancer
symbols :
NVS
save search
New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients
Published:
2022-05-04
(Crawled : 08:00)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
12.32%
|
O:
-0.1%
H:
0.0%
C:
0.0%
kisqali
novartis
cancer
breast cancer
her2-
her2
Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
Published:
2021-12-10
(Crawled : 13:00)
- globenewswire.com
NVSEF
|
News
|
$96.0
0.94%
6.88%
0
|
Health Technology
|
18.2%
|
O:
-1.81%
H:
0.0%
C:
-0.31%
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
21.59%
|
O:
-0.49%
H:
0.0%
C:
0.0%
piqray
novartis
media
cancer
breast cancer
her2-
her2
metastatic breast cancer
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
Published:
2021-12-08
(Crawled : 15:00)
- globenewswire.com
NVSEF
|
News
|
$96.0
0.94%
6.88%
0
|
Health Technology
|
20.33%
|
O:
1.8%
H:
0.0%
C:
0.0%
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
21.9%
|
O:
1.04%
H:
0.0%
C:
0.0%
kisqali
genomic
cancer
breast cancer
her2-
her2
metastatic breast cancer
Breast Cancer Drugs Global Market Report 2021
Published:
2021-11-12
(Crawled : 11:00)
- prnewswire.com
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
18.57%
|
O:
-0.3%
H:
0.0%
C:
0.0%
LLY
|
News
|
$732.2
-1.81%
-0.84%
1.7M
|
Health Technology
|
185.98%
|
O:
-0.49%
H:
0.0%
C:
0.0%
cancer drug
cancer
drug
breast cancer
market
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Published:
2021-09-19
(Crawled : 16:20)
- globenewswire.com
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
media
cancer
breast cancer
her2+
her2-
her2
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Published:
2021-06-02
(Crawled : 14:00)
- biospace.com/
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
11.61%
|
O:
0.85%
H:
0.37%
C:
0.02%
media
cancer
breast cancer
her2+
her2-
her2
metastatic breast cancer
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Published:
2021-05-19
(Crawled : 22:00)
- prnewswire.com
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
12.19%
|
O:
-0.46%
H:
1.21%
C:
0.78%
INCY
|
$51.74
0.17%
0.14%
1.6M
|
Health Technology
|
-36.68%
|
O:
0.12%
H:
3.3%
C:
2.08%
cancer
breast cancer
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
Published:
2021-03-18
(Crawled : 12:30)
- biospace.com/
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
14.84%
|
O:
-0.56%
H:
0.83%
C:
0.02%
women
cancer
breast cancer
her2+
her2-
her2
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
Published:
2021-03-16
(Crawled : 01:00)
- biospace.com/
NVS
|
News
|
$98.35
1.1%
0.69%
2.1M
|
Health Technology
|
15.31%
|
O:
0.14%
H:
0.82%
C:
0.7%
CELC
|
$16.94
-1.74%
-2.01%
90K
|
Commercial Services
|
25.48%
|
O:
1.19%
H:
6.37%
C:
0.66%
new drug
collaboration
cancer
biotech
drug
iot
breast cancer
trial
Gainers vs Losers
61%
39%
Top 10 Gainers
CSSE
4
|
$0.4253
179.25%
64.77%
210M
|
Consumer Services
BOF
|
$2.08
77.78%
41.21%
110M
|
ILAG
|
$0.54
12.27%
40.62%
3.7M
|
LICN
|
$0.999
78.39%
40.49%
15M
|
AMST
|
$3.4
70.0%
39.58%
70M
|
Technology Services
MTC
|
$3.6
60.71%
38.04%
9.1M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.458
14.5%
30.92%
91K
|
Health Services
WHLM
|
$6.25
35.87%
28.46%
700K
|
Commercial Services
MULN
|
News
|
$3.77
38.1%
27.78%
13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.